Follow WOWNEWS 24x7 on:
Zydus Lifesciences has received tentative approval from the USFDA to market Bosentan Tablets for Oral Suspension, 32 mg (reference listed drug: Tracleer®). The drug is indicated for treating pulmonary arterial hypertension (PAH) in pediatric patients aged three and above. Manufactured at Zydus’ Ahmedabad facility, this approval strengthens its US generics portfolio.
Show moreStay Ahead – Explore Now! Blackstone Leads $1.2 Billion Funding in Neysa to Build India’s AI Infrastructure Platform
Updated: February 18, 2026 18:18
Updated: February 17, 2026 18:19
Updated: February 15, 2026 18:16
Follow WOWNEWS 24x7 on:
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
